Physician profile
Dan Neil Olson
NPI 1417981077
$5,140.57
in general payments reported to CMS, 2019-2025
43 companies · $574 in 2025
The $574 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $823 · 2021: $1,440 · 2022: $795 · 2023: $277 · 2024: $371 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,222.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $574.38 | 2019-2021 | |
| Amgen INC. | $562.61 | 2019-2025 | Prolia, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $445.24 | 2019-2025 | Airsupra, Breztri |
| Abbvie INC. | $430.06 | 2021-2025 | |
| Pfizer INC. | $236.80 | 2019-2025 | |
| Abbott Laboratories | $201.23 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $199.34 | 2019-2025 | Verquvo |
| Novo Nordisk INC | $190.49 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $179.12 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $160.89 | 2021-2022 | |
| Glaxosmithkline, LLC. | $160.28 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $146.57 | 2019-2022 | |
| Lundbeck LLC | $145.07 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $131.50 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $119.49 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.